A detailed history of Silvercrest Asset Management Group LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 124,117 shares of NVO stock, worth $13.1 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
124,117
Previous 118,870 4.41%
Holding current value
$13.1 Million
Previous $17 Million 12.9%
% of portfolio
0.1%
Previous 0.12%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$119.07 - $145.42 $624,760 - $763,018
5,247 Added 4.41%
124,117 $14.8 Million
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $14.6 Million - $17.5 Million
-118,870 Reduced 50.0%
118,870 $17 Million
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $12.7 Million - $15.2 Million
103,680 Added 77.34%
237,740 $33.9 Million
Q1 2024

May 15, 2024

BUY
$102.11 - $135.92 $1.13 Million - $1.5 Million
11,020 Added 8.96%
134,060 $17.2 Million
Q4 2023

Feb 14, 2024

BUY
$87.78 - $105.45 $1.56 Million - $1.87 Million
17,733 Added 16.84%
123,040 $12.7 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $4.53 Million - $9.94 Million
49,817 Added 89.78%
105,307 $9.58 Million
Q2 2023

Aug 14, 2023

SELL
$155.98 - $172.65 $689,431 - $763,113
-4,420 Reduced 7.38%
55,490 $8.98 Million
Q1 2023

May 15, 2023

SELL
$132.34 - $159.14 $2.1 Million - $2.53 Million
-15,888 Reduced 20.96%
59,910 $9.53 Million
Q4 2022

Feb 14, 2023

BUY
$102.55 - $135.33 $1.65 Million - $2.18 Million
16,083 Added 26.93%
75,798 $10.3 Million
Q3 2022

Nov 14, 2022

SELL
$95.28 - $116.93 $231,244 - $283,789
-2,427 Reduced 3.91%
59,715 $5.95 Million
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $685,720 - $809,062
6,642 Added 11.97%
62,142 $6.92 Million
Q1 2022

May 16, 2022

BUY
$93.1 - $112.54 $20,761 - $25,096
223 Added 0.4%
55,500 $6.16 Million
Q4 2021

Feb 14, 2022

BUY
$95.88 - $117.08 $2.03 Million - $2.48 Million
21,214 Added 62.28%
55,277 $6.19 Million
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $636,526 - $803,914
7,540 Added 28.43%
34,063 $3.27 Million
Q2 2021

Aug 16, 2021

SELL
$67.66 - $84.76 $11,163 - $13,985
-165 Reduced 0.62%
26,523 $2.22 Million
Q1 2021

May 17, 2021

SELL
$67.06 - $75.82 $55,659 - $62,930
-830 Reduced 3.02%
26,688 $1.8 Million
Q4 2020

Feb 16, 2021

BUY
$63.89 - $73.8 $82,226 - $94,980
1,287 Added 4.91%
27,518 $1.92 Million
Q3 2020

Nov 16, 2020

BUY
$63.69 - $70.22 $70,313 - $77,522
1,104 Added 4.39%
26,231 $1.82 Million
Q2 2020

Aug 14, 2020

BUY
$58.54 - $67.94 $44,022 - $51,090
752 Added 3.09%
25,127 $1.65 Million
Q1 2020

May 15, 2020

SELL
$49.46 - $64.78 $4,154 - $5,441
-84 Reduced 0.34%
24,375 $1.47 Million
Q4 2019

Feb 14, 2020

SELL
$49.86 - $58.26 $7,728 - $9,030
-155 Reduced 0.63%
24,459 $1.42 Million
Q3 2019

Nov 14, 2019

BUY
$47.54 - $53.43 $9,270 - $10,418
195 Added 0.8%
24,614 $1.27 Million
Q2 2019

Aug 14, 2019

BUY
$46.79 - $52.47 $11,136 - $12,487
238 Added 0.98%
24,419 $1.25 Million
Q1 2019

May 15, 2019

SELL
$46.36 - $52.63 $1.37 Million - $1.56 Million
-29,654 Reduced 55.08%
24,181 $1.27 Million
Q4 2018

Feb 14, 2019

BUY
$41.54 - $47.25 $9,969 - $11,340
240 Added 0.45%
53,835 $2.48 Million
Q3 2018

Nov 14, 2018

SELL
$46.76 - $51.24 $510,432 - $559,335
-10,916 Reduced 16.92%
53,595 $2.53 Million
Q2 2018

Aug 14, 2018

BUY
$44.29 - $50.42 $55,893 - $63,630
1,262 Added 2.0%
64,511 $2.98 Million
Q1 2018

May 15, 2018

BUY
$48.49 - $58.14 $112,254 - $134,594
2,315 Added 3.8%
63,249 $3.12 Million
Q4 2017

Feb 14, 2018

BUY
$47.53 - $53.73 $84,365 - $95,370
1,775 Added 3.0%
60,934 $3.27 Million
Q3 2017

Nov 14, 2017

BUY
$41.15 - $49.22 $2.43 Million - $2.91 Million
59,159
59,159 $2.85 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $238B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.